Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total transaction of $503,250.00. Following the sale, the chief executive officer owned 2,262,500 shares of the company’s stock, valued at $227,720,625. This trade represents a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

iRadimed Stock Performance

Shares of iRadimed stock traded down $0.26 during trading hours on Tuesday, reaching $99.84. The company’s stock had a trading volume of 40,569 shares, compared to its average volume of 80,175. The stock’s fifty day simple moving average is $96.45 and its two-hundred day simple moving average is $80.27. The company has a market capitalization of $1.27 billion, a P/E ratio of 60.51 and a beta of 1.09. iRadimed Corporation has a one year low of $47.48 and a one year high of $104.93.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IRMD. Zacks Research raised shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reissued a “buy” rating and set a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm set a $90.00 price objective on shares of iRadimed in a research note on Friday, October 31st. Finally, Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $95.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IRMD. CWM LLC increased its stake in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP bought a new position in iRadimed in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC grew its stake in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 397 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new stake in shares of iRadimed during the third quarter worth $47,000. 92.34% of the stock is owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.